Replies to post #147044 on Biotech Values

[exwannabe]

ARRY:

I dun see anything new in the PR up 6% !? Am I missing something?

I do not remember the primary endpoint for the oxycondone ITT arm being previously published. Did I miss it?

I know most discount this drug, but if it really is as effective as oxy, and the QT issue is turns out to be insiggnificant, then it certainly could have some real potential.